A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

Launched by UNIVERSITY HOSPITAL, ANTWERP · Jul 22, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the experiences of patients with Barrett's Esophagus, a condition that can increase the risk of developing esophageal cancer. The study aims to collect and analyze tissue samples, including blood and biopsies, to improve methods for predicting cancer development in these patients. Additionally, it will assess how living with Barrett's Esophagus affects patients' quality of life and their fears about cancer.

To join the study, participants must be at least 18 years old, able to give informed consent, and have Barrett's Esophagus, particularly if they are being evaluated for possible early-stage esophageal cancer. During the study, participants will have an initial consultation, followed by a routine endoscopy where a blood sample will be taken, and cells will be collected from their esophagus using a small brush, along with biopsy samples. It's important to note that the trial is not yet recruiting participants, and individuals with certain health conditions or recent cancer treatments may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of early esophageal Barrett cancer
• • Capable of receiving informed consent and of giving permission
• • Age 18 and upward
• Exclusion Criteria:
• • Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion
• • Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)
• • Esophageal varices
• • Uncontrollable coagulation disorders
• • Undergoing chemotherapy or immunotherapy or received chemotherapy \< 6 weeks prior to endoscopy
• • Undergoing radiotherapy within the esophageal region or received chemotherapy \< 6 months prior to endoscopy
• • WHO score \> 3